Preliminary report of the use on adults of a recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan.
Rev Inst Med Trop Sao Paulo
; 39(1): 39-42, 1997.
Article
em En
| MEDLINE
| ID: mdl-9394535
Three 10 micrograms of the recombinant hepatitis B vaccine, manufactured by Instituto Butantan by original technology, were administered in an adult population, mean age 30 years old, following the 0, 1 and 6 months schedule immunization. The clinical trial was considered satisfactory in terms of immunogenicity (anti-HBs titers between 17.5-29500 IU/ l, seroconversion 95.3%) and reactogenicity (no incapacitating side effects).
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leveduras
/
Vacinas Sintéticas
/
Vacinas contra Hepatite B
/
Hepatite B
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Humans
/
Middle aged
Idioma:
En
Revista:
Rev Inst Med Trop Sao Paulo
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil